Petrelintide Phase 2 trial (NCT06926842)
A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 221
- actual
- Start
- 22 Apr 2025 (actual)
- Primary completion
- 13 Aug 2026 (actual)
- Sponsor
- Zealand Pharma
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Treatment A: Petrelintide Dose 1 | Experimental | Drug: Petrelintide | Randomized participants will receive weekly subcutaneous injections of petrelintide Dose 1. |
| Treatment B: Petrelintide Placebo Dose 1 | Placebo comparator | Other: Placebo | Randomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide. |
| Treatment C: Petrelintide Dose 2 | Experimental | Drug: Petrelintide | Randomized participants will receive weekly subcutaneous injections of petrelintide Dose 2. |
| Treatment D: Petrelintide Placebo Dose 2 | Placebo comparator | Other: Placebo | Randomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide. |
| Treatment E: Petrelintide Dose 3 | Experimental | Drug: Petrelintide | Randomized participants will receive weekly subcutaneous injections of petrelintide Dose 3. |
| Treatment F: Petrelintide Placebo Dose 3 | Placebo comparator | Other: Placebo | Randomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage Change in Body Weight | From Baseline (Day 1) to Weeks 28 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Number of Participants Achieving ≥5% Body Weight Loss | From Baseline (Day 1) to Weeks 28 |
| Number of Participants Achieving ≥10% Body Weight Loss | From Baseline (Day 1) to Weeks 28 |
| Change in Body Weight (kilogram) | From Baseline (Day 1) to Weeks 28 |
| Change in Waist Circumference | From Baseline (Day 1) to Weeks 28 |
| Change in Glycated Hemoglobin (HbA1c) | From Baseline (Day 1) to Weeks 28 |
| Change in Fasting Glucose | From Baseline (Day 1) to Weeks 28 |
| Change in High-Sensitivity C-reactive protein (hsCRP) | From Baseline (Day 1) to Weeks 28 |
| Number of Participants Achieving ≤6.5% HbA1c | From Baseline (Day 1) to Weeks 28 |
| Changes in Fasting Lipids | From Baseline (Day 1) to Weeks 28 |
| Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | From Baseline (Day 1) to Weeks 38 |
| Number of Participants with Treatment- Emergent Severe or Clinically Significant Hypoglycemic Episodes from Baseline to Week 38 | From Baseline (Day 1) to Weeks 38 |
| Number of Participants with Positive Anti-Drug Antibodies (ADAs) | From Baseline (Day 1) to Weeks 38 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.